Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Meghna A Singhania
    Meghna A Singhania

      Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

      • Home
      • Meghna A Singhania

      Articles By : Meghna A Singhania

      After 11 years, Dr Reddys Lab gets Chinese regulator nod for generic Clopidogrel

      After 11 years, Dr Reddys Lab gets Chinese regulator nod for generic Clopidogrel

      Meghna A Singhania24 April 2019 12:06 PM IST
      Hyderabad: After a decade long wait, Dr Reddy's Laboratories (Dr Reddys) has finally bagged the approval from the Chinese regulator for its anti-blood...
      Now State Drug Controllers to have authority to issue STOP SALE order of Medicines: CDSCO to amend to rule

      Now State Drug Controllers to have authority to issue STOP SALE order of Medicines: CDSCO to amend to rule

      Meghna A Singhania23 April 2019 12:20 PM IST
      New Delhi: Empowering State Drug Controllers, the Government will soon amend Rule 66 of Drugs and Cosmetics (D&C) Rules, 1940 thereby granting...
      Patent Infringement: Cadila Healthcare, two others prohibited from launching Linagliptin Metformin Hydrochloride tablets

      Patent Infringement: Cadila Healthcare, two others prohibited from launching Linagliptin Metformin Hydrochloride tablets

      Meghna A Singhania22 April 2019 2:07 PM IST
      AHMEDABAD: In a major setback, three Gujarat based pharmaceutical companies including Cadila Healthcare, West Coast Pharmaceutical Works Ltd and Maan...
      Drugs registered on SUGAM portal to be exempted from obtaining licence for purpose of examination, test, analysis

      Drugs registered on SUGAM portal to be exempted from obtaining licence for purpose of examination, test, analysis

      Meghna A Singhania21 April 2019 2:26 PM IST
      The exemption from obtaining a licence for Form 29 is subject to the condition that the information about the manufacturing of approved drugs for...
      Chemists and Druggists or Pharmacy? DTAB decides on nomenclature

      Chemists and Druggists or Pharmacy? DTAB decides on nomenclature

      Meghna A Singhania20 April 2019 11:44 AM IST
      New Delhi: The highest statutory decision-making body under CDSCO, Drug Technical Advisory Board (DTAB) has given its in principal nod to replace the...
      Mandatory QR coding for APIs soon: DTAB

      Mandatory QR coding for APIs soon: DTAB

      Meghna A Singhania19 April 2019 11:21 AM IST
      New Delhi: Drugs Technical Advisory Board (DTAB), functional under the Central Drugs and Standard (CDSCO) has recommended “making it mandatory to have...
      Government to revise limit of free salicylic acid content in drugs containing ASPIRIN

      Government to revise limit of free salicylic acid content in drugs containing ASPIRIN

      Meghna A Singhania18 April 2019 3:13 PM IST
      New Delhi: Government is soon going to revise the limit of free salicylic acid content in medicines containing Aspirin, as the Drugs and Techincal...
      All medical devices sold in India to be CDSCO certified: What is Means

      All medical devices sold in India to be CDSCO certified: What is Means

      Meghna A Singhania18 April 2019 2:59 PM IST
      Once this notification comes into effect, the manufacture and sale of all medical devices would have to be certified by the Central Drugs Standard...
      Adverse Reactions: Cefotaxime, Oflaxicin, Cefixime told to carry Warning by CDSCO

      Adverse Reactions: Cefotaxime, Oflaxicin, Cefixime told to carry Warning by CDSCO

      Meghna A Singhania17 April 2019 12:26 PM IST
      New Delhi: The national regulatory body for Indian Pharmaceutical and Medical Device, Central Drugs Standard Control Organisation (CDSCO) has ordered...
      Alchem solves stability dilemma for micronized DIGOXIN; files PATENT for novel production process

      Alchem solves stability dilemma for micronized DIGOXIN; files PATENT for novel production process

      Meghna A Singhania16 April 2019 4:47 PM IST
      Alchem's molecule is the sole micronized digoxin available globally that resolves the challenge of micro dosage formulation and the long-term...
      CDSCO expert committee suggests ban of yet another 324 FDCs

      CDSCO expert committee suggests ban of yet another 324 FDCs

      Meghna A Singhania15 April 2019 11:49 AM IST
      New Delhi: Domestic drugmakers are likely to face a blow as 324 Fixed Dose Combination (FDCs) drugs have been recommended to be banned by an expert...
      MMC develops potential TB drugs; awaits permission from CDSCO for mass manufacture

      MMC develops potential TB drugs; awaits permission from CDSCO for mass manufacture

      Meghna A Singhania14 April 2019 4:00 PM IST
      Chennai: In a major breakthrough, the Madras Medical College (MMC) has developed not just one but two anti-tuberculosis drug formulations. According...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok